Avita Medical

156 articles with Avita Medical

• Avita Medical First Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update

  10/31/2018

  FDA approval of RECELL® System for the treatment of acute thermal burns in adults

• AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries

  10/25/2018

  Clinical study is being conducted in Brisbane, Australia, in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital

• AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping

  10/18/2018

  Multiple U.S. burn centers incorporating RECELL System into their practices in advance of national U.S. market launch

• AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn Conference

  10/15/2018

  AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System)

• AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

  9/26/2018

  AVITA Medical announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017.

• AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.

  9/21/2018

  Point-of-care regenerative medicine technology approved to treat second- and third-degree burns using Spray-On Skin™ Cells product

• AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch

  8/23/2018

  AVITA Medical today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California.

• AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military Conference

  8/22/2018

  Results from two U.S. pivotal trials featured in plenary session at U.S. Defense Department Military Health System Research Symposium

• AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns

  8/9/2018

  FDA approves expansion of program to include up to 108 patients and 26 U.S. burn centers

• AVITA Medical Announces Results of Extraordinary General Meeting

  7/23/2018

  ​Avita Medical, a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications, announced that both resolutions presented to shareholders were approved at an Extraordinary General Meeting held today.

• AVITA Medical Announces Expansion of Management Team to Support Planned U.S. Launch of RECELL® Device

  7/20/2018

  AVITA Medical announced that it expanded its management team in the commercial, legal and medical affairs functions to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns.

• AVITA Medical RECELL® Device Pivotal Trial Results in Second-Degree Burns Published in Journal of Burn Care & Research

  6/26/2018

  ​Trial demonstrated statistically significant reduction in donor skin requirements and pain, increased patient satisfaction, and improved donor scar outcomes

• AVITA Medical Announces Institutional Placement of A$16.0 Million to Support U.S. Commercialization of the RECELL® Device

  6/6/2018

  AVITA Medical today announced an institutional placement of A$16.0 million to prepare for the planned U.S. launch of the RECELL® Device in the treatment of severe burns.

• AVITA Medical Announces Schedule for Six RECELL® Device Presentations at American Burn Association (ABA) 50th Annual Meeting

  4/3/2018

  Avita Medical announced new data to be presented describing clinical and cost-savings advantages of RECELL® Device in the treatment of severe burns at the American Burn Association (ABA) 50th Annual Meeting to be held from April 10 through 13, 2018 at the Hyatt Regency Chicago in Chicago.

• AVITA Medical Announces MIHS Burn Center Press Conference Regarding RECELL® Treatment of Patient with Necrotizing Fasciitis (Flesh Eating Bacteria)

  3/22/2018

  Avita Medical announced that Maricopa Integrated Health System (MIHS) Burn Center will hold a press conference today to highlight the recent treatment with RECELL® of a woman with necrotizing fasciitis, or flesh eating bacteria.

• AVITA Medical Announces Government Funded Clinical Trial of RECELL® in China

  3/19/2018

  Avita Medical announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns in China.

• AVITA Medical Announces FDA Approval of Expansion of RECELL Compassionate Use Program in Life Threatening Injuries

  2/12/2018

  This reduction in donor site skin requirements has important benefits from both clinical and health economic perspectives.

• Avita Medical Second Quarter 2018 Quarterly Cash Flow Report and Company Update

  1/31/2018

  Avita Medical announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 31 December 2017.

• Avita Medical Announces Five RECELL Abstracts Accepted for Presentation at American Burn Association (ABA) 50th Annual Meeting

  1/30/2018

  Avita Medical announced that five abstracts highlighting the compelling clinical data and health economic benefits of RECELL in the treatment of burns have been accepted for presentation at the American Burn Association 50th Annual Meeting to be held from April 10 through 13, 2018 in Chicago, Illinois.

• Avita Announces New CFO, Existing CFO Moves to Chief Administrative Officer

  12/5/2017

  Dale will be responsible for overseeing the global finance and investor relations functions, and aligning them with the company’s commercialization strategy.